Tubeless Insulin Pumps for 2027: MiniMed Fit and Tandem Mobi Join Omnipod 5
The FDA cleared two tubeless insulin pumps with up to 7 days of wear in November 2026. How MiniMed Fit, Tandem Mobi Tubeless, and Omnipod 5 compare on wear time, insulin capacity, sensors, ages, and pharmacy coverage, and what nobody knows yet.
Key points
- MiniMed announced FDA clearance of MiniMed Fit, its first tubeless pump, on November 16, 2026: up to 7 days of wear, a 300-unit reservoir, type 1 and type 2 diabetes from age 7, with a phased U.S. rollout expected in spring 2027
- Tandem disclosed FDA clearance of a tubeless option for its Mobi pump on November 13, 2026; the tubeless infusion set is cleared for up to 7 days, but the 200-unit cartridge is cleared for 3 days
- Omnipod 5, already on the market, lasts up to 3 days, holds up to 200 units, and is indicated for type 1 diabetes from age 2 and type 2 diabetes from age 18
- MiniMed Fit's 7-day wear depends on using under 42 units of insulin a day, per the company's footnote
- All three tubeless systems are sold, or will be sold, through pharmacy coverage; Medicare Part B does not cover disposable patch pumps, and Part D may cover the insulin used in them
- The ADA's 2026 Standards call AID the preferred insulin delivery method for type 1 diabetes and adults with type 2 diabetes, compared with injections or nonautomated pumps
- No prices or real-world outcome data for MiniMed Fit or Mobi Tubeless were available at clearance
The short version
Two companies announced FDA clearance of tubeless insulin pumps within four days in November 2026. Tandem Diabetes Care disclosed on Friday, November 13, that the agency had cleared a tubeless option for its Mobi pump. On Monday, November 16, MiniMed announced clearance of MiniMed Fit, its first tubeless pump. MiniMed has been an independent company since October 2026, when Medtronic finished spinning it off.
Both join Insulet's Omnipod 5, the tubeless system already on the market, and Beta Bionics' Mint, a patch pump the FDA cleared in September. Insulet "has dominated new device starts with its patch pump," MedTech Dive wrote when Mint was cleared.
You cannot buy either new device yet. MiniMed expects a phased U.S. rollout in spring 2027, and Tandem plans its full launch in the first half of 2027. This guide is for people with type 1 diabetes, people with type 2 diabetes who use insulin, and parents. Insulin, the drug every one of these pumps delivers, is a peptide hormone, which is why this site covers it. For related reading, see GLP-1 drugs in type 1 diabetes and the insulin pumps news tag.
Tubed and tubeless pumps
An insulin pump delivers rapid-acting insulin under the skin around the clock, replacing most or all daily injections. In a tubed pump, the insulin sits inside a device people clip to clothing or carry in a pocket. Thin tubing runs from the pump to an infusion set, a small adhesive patch that holds a soft tube called a cannula under the skin. The American Diabetes Association's 2026 Standards of Care note that most pumps use tubing and a few attach directly to the skin.
A tubeless pump, also called a patch pump or pod, sticks to the skin and holds the insulin and the cannula in one wearable unit. Nothing hangs off the body. The whole unit, or at least its insulin supply, is replaced on a fixed schedule.
Tandem's design sits between the two. Its new option replaces Mobi's infusion set with a disposable on-body kit, MedTech Dive reported, so the same pump can be worn tubed or tubeless. Current Mobi users can switch by changing their supply order, Tandem says.
What automated insulin delivery does
All three systems compared here are automated insulin delivery (AID) systems. AID has three parts: a pump, a continuous glucose monitor (CGM, a wearable sensor that reads glucose under the skin every few minutes), and software that decides how much insulin to give. According to the ADA, current systems raise, lower, or pause insulin based on where glucose is heading, either by changing the background rate or by giving small doses every 5 minutes.
Insulin dosing has two parts. Basal insulin is the steady background amount the body needs between meals and overnight. A bolus is an extra dose for a meal or to bring down a high reading. AID handles much of the basal side and gives automatic correction doses, but the ADA notes that users still have to enter carbohydrates or announce meals. MiniMed says Fit's Meal Detection feature can add insulin when a meal dose is missed or too small.
The ADA's 2026 Standards call AID the preferred way to deliver insulin for people with type 1 diabetes and adults with type 2 diabetes, compared with multiple daily injections or a pump without automation. They also say to consider AID for some people with type 2 diabetes who take only basal insulin and are not reaching their glucose goals. Which system to pick, the ADA says, depends on each person's circumstances and preferences.
How the three systems compare
| MiniMed Fit | Tandem Mobi Tubeless | Omnipod 5 | |
|---|---|---|---|
| FDA status | Cleared; announced Nov. 16, 2026 | Cleared; disclosed Nov. 13, 2026 | On the market |
| Wear time | Up to 7 days; 7 days requires under 42 units of insulin a day | Infusion set up to 7 days; cartridge cleared for 3 days | Up to 3 days (72 hours) |
| Insulin capacity | 300 units | 200 units | Up to 200 units |
| Ages and diabetes type | Type 1 and type 2, ages 7 and older | Type 1, ages 2 and older; type 2, ages 18 and older | Type 1, ages 2 and older; type 2, ages 18 and older |
| Compatible CGMs | MiniMed Simplera Sync or Abbott Instinct | Dexcom G7 (G7 15 Day for ages 18 and older) | Dexcom G7, FreeStyle Libre 3 Plus, FreeStyle Libre 2 Plus; Dexcom G6 while it remains available |
| Software | SmartGuard | Control-IQ+ | SmartAdjust |
| Insulins listed | Humalog, NovoLog, Admelog | NovoLog or Humalog U-100 | U-100 rapid-acting insulin |
| How it is sold | Pharmacy benefit | Tubeless supplies only for customers with pharmacy coverage | Pharmacy |
| U.S. availability | Phased rollout expected spring 2027 | Full launch planned for first half of 2027 | Available now |
Sources: MiniMed Fit column from MiniMed's November 16 release and Fit product page. Tandem column from Tandem's Mobi Tubeless page, Mobi page, and MedTech Dive. Omnipod 5 column from Insulet's Omnipod 5 page.
The headline numbers hide two details. MiniMed's footnote says 7-day wear is achievable with a total daily dose under 42 units. Someone who uses more insulin will empty the 300-unit reservoir sooner and change the pump more often. Tandem's 7 days applies to the tubeless infusion set; the company's own footnote says the cartridge is cleared for 3 days, so the insulin supply still gets changed midweek.
Each company calls its device the world's first and only. Tandem's claim is the first tubeless AID system with up to 7 days of wear; MiniMed's adds "zero interruptions," meaning no charging or cartridge change that week. No independent study has compared the devices.
Mint, the fourth tubeless option, has 3-day wear and a 200-unit reservoir and is due for a full U.S. launch in the first quarter of 2027, MedTech Dive reported.
Pharmacy benefit or DME: how pumps get paid for
Health plans pay for pumps in two ways. Durable medical equipment (DME) coverage, part of the medical benefit, treats a pump as a long-lasting device bought through a medical supplier. Pharmacy coverage treats the pump and supplies like a prescription.
All three tubeless systems are sold through pharmacies. MiniMed says Fit will be available through the pharmacy benefit. Insulet says Omnipod 5's pharmacy route lets people switch at almost any time, depending on their coverage. Tandem will sell tubeless Mobi supplies only to customers with pharmacy coverage and estimates that Mobi pharmacy coverage reaches about half of insured people in the U.S., MedTech Dive reported. Tandem also offers a copay card worth up to $100 a month for 12 months toward infusion sets and cartridges, which is not available to people on Medicare, Medicaid, TRICARE, or Kaiser plans.
Medicare uses both routes. Medicare.gov says Part B covers insulin pumps under its DME benefit but does not cover disposable patch pumps or the insulin used in them. A Part D drug plan may cover insulin used with patch pumps and with certain reusable pumps that use disposable cartridges. A one-month supply of each covered insulin product costs no more than $35 under either part.
Questions to ask your plan or pharmacy benefit manager before choosing:
- Is this specific pump covered under my pharmacy benefit, my DME benefit, or neither?
- Does it need prior authorization, and what will my doctor have to document?
- What will I pay for the starter kit, and for a month of pods, cartridges, or infusion sets?
- If I bought a tubed pump through DME recently, will the plan pay for a tubeless system now?
- Is my CGM covered under the same benefit?
- Is there a monthly limit on pods or cartridges? That matters if you use a lot of insulin.
Who might not suit a pump
The ADA says there is no consensus on which factors best predict success with a pump or AID. It does say safe use requires understanding the system and knowing how to troubleshoot it. If a cannula comes loose or gets blocked, insulin stops flowing, and the person is at risk of ketosis and diabetic ketoacidosis (DKA), a dangerous buildup of acids in the blood that must be caught early.
Skin is another limit. The ADA reports irritant and allergic reactions with every device that attaches to the skin, in some cases linked to an adhesive ingredient called isobornyl acrylate. People on AID wear a pump and a sensor, and the new pumps ask one patch to hold for up to a week.
The labels set limits too. Tandem and Insulet say their automation should not be used by anyone who needs less than 5 units of insulin a day, and Tandem adds a minimum body weight of 20 pounds. MiniMed Fit is cleared from age 7, so among these three, a child aged 2 to 6 could use Omnipod 5 or Mobi. The ADA lists the current reasons people stop pump therapy: cost or wearability, lost insurance, disliking the pump, poor glucose results, or anxiety and depression. Talk these through with your diabetes care team before you order.
Canada loosens pump rules
The FDA decisions apply to the U.S. market. In Canada, provincial programs pay for many pumps, and two changes came around World Diabetes Day on November 14. Starting February 1, 2027, Ontario's Assistive Devices Program will stop requiring people to inject insulin for a year before it funds a pump, and will renew pump grants every two years instead of every year, the Sydenham Current reported. The province says nearly 4,000 people a year will qualify up to a year sooner. The program fully funds approved pumps for eligible people with type 1 diabetes and pays $2,400 a year toward supplies.
In Alberta, the Edmonton Diabetes and High Risk Foot Clinic now lets people with type 1 diabetes book a pump consultation without a referral, Global News reported. The clinic says it has no waitlist and most patients can be on a pump in about two months. Both stories appeared in our November 15 digest, and MiniMed Fit in the November 16 digest.
What is not known yet
Price. Neither MiniMed's release nor Tandem's Mobi Tubeless page gave a price for the new pumps or their monthly supplies. What you pay will depend on your plan's pharmacy coverage.
Results on the new devices. MiniMed's figures of up to 80% time in range and 91% overnight come from real-world users of its SmartGuard software on the MiniMed 780G system, according to the release's own references, and MiniMed warns that real-world results may not carry over to new patients. Tandem's outcome claims on its Mobi pages cite studies run on its t:slim X2 pump with an older Dexcom G6 sensor. How well a 7-day patch stays on will only become clear after launch.
Reliability. On November 11, MedTech Dive reported that Tandem had issued a correction for more than 80,900 Mobi pumps because of false occlusion alarms, which pause insulin until the user responds. As of October 29, Tandem had received 230 reports of adverse events requiring medical intervention or hospitalization, and no deaths. Tandem told users they could keep using the pumps but must respond to every occlusion alarm and keep a backup way to take insulin. Because the tubeless option runs on the same Mobi pump, ask Tandem or your care team whether your pump is affected.
Supply. MiniMed plans an early customer phase before its wider rollout. Tandem plans a limited launch first, which William Blair analysts said will let it build manufacturing capacity. Early access may be limited.
Limitations
- Device specifications come from manufacturer press releases and product pages; FDA clearance summaries for MiniMed Fit and Mobi Tubeless were not reviewed
- Tandem's own press release on the clearance was not accessible; Tandem details come from its product pages and MedTech Dive's report
- Time-in-range figures cited by the companies come from earlier pumps or algorithms, not from the newly cleared tubeless devices
- Insurance coverage varies by plan; the pharmacy coverage estimate for Mobi is a company figure
- Canadian program details come from local news coverage of provincial announcements, not from the provincial releases themselves
Citations
- 1. FDA Clears MiniMed Fit -- World's First and Only Tubeless Insulin Pump with Up to Seven-Day Wear and Zero Interruptionspress-release MiniMed via PR Newswire 2026
- 2. MiniMed Fit tubeless insulin pump system (product page)manufacturer MiniMed 2026
- 3. Tandem wins FDA clearance for tubeless automated insulin delivery systemnews MedTech Dive 2026
- 4. Tandem Mobi Tubeless Insulin Pump (product page)manufacturer Tandem Diabetes Care 2026
- 5. Tandem Mobi automated insulin delivery system (product page)manufacturer Tandem Diabetes Care 2026
- 6. Omnipod 5 Automated Insulin Delivery System (product page)manufacturer Insulet 2026
- 7. Beta Bionics insulin patch pump gets FDA nodnews MedTech Dive 2026
- 8. Tandem recalls Mobi insulin pump, reports 230 adverse eventsnews MedTech Dive 2026
- 9. 7. Diabetes Technology: Standards of Care in Diabetes-2026guideline Diabetes Care 2026
- 10. Insulin coverage (Medicare Part B and Part D)government Medicare.gov 2026
- 11. Medtronic statement on completion of MiniMed separation (Form 8-K, Exhibit 99.1)company-filing Medtronic via SEC 2026
- 12. Edmonton clinic launches Alberta's first self-referral insulin pump programnews Global News 2026
- 13. Ontario to expand insulin pump funding, remove one-year injection requirementnews Sydenham Current 2026
Peptides in this article
Full peptide profiles with evidence levels, dosing data, and safety notes live on peptidelist.org.